AEON Biopharma, Inc. (AEON) Investor Relations Documents

AEON Biopharma, Inc. (AEON) investor relations documents from the company's IR site: 1 presentation, 23 press releases; latest deck 2026-08-11. Read in-app with summaries. First-party data.

Corporate Presentation: AEON Biopharma's ABP-450 aims to disrupt the $3.5B neurotoxin market with a BOTOX® substitute, targeting full-label approval by Aug 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-19Press releaseAEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
2026-08-12Press releaseAEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-11PresentationCorporate Presentation
2026-08-03Press releaseAEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
2026-07-14Press releaseAEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providin
2026-06-04Press releaseAEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th An
2026-05-14Press releaseAEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-04-24Press releaseAEON Biopharma Sets Annual Shareholder Meeting
2026-04-03Press releaseAEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
2026-04-03Press releaseAEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
2026-03-30Press releaseAEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA F
2026-03-25Press releaseAEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
2026-03-09Press releaseAEON Biopharma Appoints John Bencich as Chief Financial Officer
2026-01-21Press releaseAEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
2025-12-15Press releaseAEON Biopharma Announces Execution of Exchange Agreement with Daewoong
2025-11-13Press releaseAEON Biopharma Reports Positive and Robust Biosimilarity Results: Identical Amino Acid Sequence and Highly Similar Funct
2025-10-01Press releaseAEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19
2024-09-30Press releaseAEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting
2024-08-19Press releaseAEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
2024-05-09Press releaseAEON Biopharma Provides Update on Development Pipeline
2024-05-03Press releaseAEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatme
2024-03-29Press releaseAEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
2024-03-19Press releaseAEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA)
2024-01-18Press releaseAEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dy

AEON overview · AEON earnings · AEON financials · AEON KPIs · AEON ownership · AEON peers · AEON filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.